DrugDashboards

epinephrine

epinephrine · EPINEPHRINE 1 mg/mL · Injection, Solution · Intramuscular; Subcutaneous · American Regent, Inc.

NDC 00517-1171-10 · 10 AMPULE in 1 BOX / 1 mL in 1 AMPULE · ANDA · View full market →

The short version

6 companies supply this market — a reasonable cushion if one runs into trouble. Historically, drugs in this position went on to a new shortage within 90 days about 0.5% of the time — roughly 4× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed
$149.60
Reported to Texas DSHS · 2026 annual filing · American Regent, Inc.

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2024)

$975
99 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.5%chance of a new FDA shortage posting for epinephrine (injectable) in the next 90 days

sterile injectable · OAI inspection at a producing facility (24 months) · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is 4× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

  • CenexiFrance
    label · manufacture

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $206.21 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA207568
TE code
—
Approval date
Jul 6, 2018
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of epinephrine (Injection, Solution)

LabelerStrengthFirst seenLast seen
Medical Purchasing Solutions, LLCEPINEPHRINE .3 mg/.3mLJul 15, 2026Sep 3, 2026
American Regent, Inc.EPINEPHRINE 1 mg/mLJul 15, 2026Sep 2, 2026
Baxter Healthcare CorporationEPINEPHRINE BITARTRATE 64 ug/mLJul 15, 2026Sep 2, 2026
Baxter Healthcare CorporationEPINEPHRINE BITARTRATE 16 ug/mLJul 15, 2026Sep 2, 2026
HF Acquisition Co LLC, DBA HealthFirstEPINEPHRINE .1 mg/.1mLJul 15, 2026Sep 2, 2026
HF Acquisition Co LLC, DBA HealthFirstEPINEPHRINE .15 mg/.15mLJul 15, 2026Sep 2, 2026
HF Acquisition Co LLC, DBA HealthFirstEPINEPHRINE .1 mg/mLJul 15, 2026Sep 2, 2026
HF Acquisition Co LLC, DBA HealthFirstEPINEPHRINE .3 mg/.3mLJul 15, 2026Sep 2, 2026
Hospira, Inc.EPINEPHRINE 1 mg/mLJul 15, 2026Sep 2, 2026
kaleo, IncEPINEPHRINE .3 mg/.3mLJul 15, 2026Sep 2, 2026
kaleo, IncEPINEPHRINE .15 mg/.15mLJul 15, 2026Sep 2, 2026
kaleo, IncEPINEPHRINE .1 mg/.1mLJul 15, 2026Sep 2, 2026
Medical Purchasing Solutions, LLCEPINEPHRINE .1 mg/mLJul 15, 2026Sep 2, 2026
Medical Purchasing Solutions, LLCEPINEPHRINE .15 mg/.15mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "epinephrine — NDC 00517-1171-10," retrieved September 3, 2026, https://drugdashboards.com/drug/00517117110.

Free to cite with attribution — see how the data is put together.